References

  1. Leape L, Abookire S, World Health Organization, et al. WHO draft guidelines for adverse event reporting and learning systems : from information to action. Geneva, Switzerland : World Health Organization. 2005.
  2. U.S. Food and Drug Administration. Guideline for Industry. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Accessed June 12, 2017.
  3. Mayo Clinic. Statistics about adverse reactions. Prevalence and incidence statistics for adverse reactions. Accessed June 12, 2017.
  4. Valhe JL, Hutto DL, Postema M. Drug discovery and preclinical development- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 919-932.
  5. Goldberg MA, Kuta AE. Clinical drug evaluation and regulatory approval- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 933-945.
  6. Conner MW, Dorian-Conner C, Vaidya VS, et al. Drug toxicity- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 70-86.
  7. Guengerich FP. Drug metabolism- Principles of Pharmacology : The Pathophysiologic Basis of Drug Therapy, 4th edition. David E Golan (Ed). Philadelphia, PA : Wolters Kluwer. 2017. 43-55.
  8. Council for International Organizations for Medical Sciences. Reporting adverse drug reactions. Definitions of terms and criteria for their use. Accessed June 12, 2017.
  9. Roswarski M, Villa KR, Kiersma ME, et al. Prevalence of Adverse Drug Effects/Adverse Drug Reactions in 200 Most Commonly Prescribed Drugs Corrected for Prescription Volume. 2009. Pharmacy Practice Faculty Presentations. 69. Accessed June 12, 2017.
  10. National Institute of Health. U.S. National Library of Medicine. DailyMed. Accessed June 12, 2017.
  11. Centers for Disease Control and Prevention. Opioid overdose. Accessed June 12, 2017.
  12. World Health Organization. Information sheet on opioid overdose. November, 2014. Accessed June 12, 2017.
  13. Ciancio SG. Medications' impact on oral health. J Am Dent Assoc. 2004 Oct;135(10):1440-8; quiz 1468-9.
  14. Jacobsen PL, Chávez EM. Clinical management of the dental patient taking multiple drugs. J Contemp Dent Pract. 2005 Nov 15;6(4):144-51.
  15. Torpet LA, Kragelund C, Reibel J, et al. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med. 2004 Jan 1;15(1):28-46.
  16. Scully C, Bagan JV. Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med. 2004 Jul 1;15(4):221-39.
  17. American Association of Oral and Maxillofacial Surgeons. Medication-Related Osteonecrosis of the Jaw - 2014 Update. Accessed June 12, 2017.
  18. Greenberger NJ. Approach to the patient with upper GI complaints – The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 70-83.
  19. Bharucha AE. Approach to the patient with lower GI complains - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 83-93.
  20. Ansari P. Acute abdominal and surgical gastroenterology - - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 105-119.
  21. Freedman SD. Pancreatitis - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 140-145.
  22. Cohen S. Gastritis and peptic ulcer disease - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 128-137.
  23. FDA Drug Safety Communication:Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. 01/13/2011 Accessed June 16, 2017
  24. Herrine SK. Navarro VJ. Drugs and the liver - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 232-235.
  25. Tucci DL. Approach to the patient with ear problems - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 413-428.
  26. Tanser PH. Approach to the cardiac patient - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2017-2047.
  27. Mitchell LB. Arrhythmias and conduction disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2142-2178.
  28. Lechtzin N. Approach to the patient with pulmonary symptoms - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1826-1847.
  29. McMillan JI. Glomerular disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2387-2411.
  30. Lui PD. Voiding disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 2352-2364.
  31. Doghramji K. Sleeping and wakefulness disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1703-1714.
  32. Coryell W. Mood disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1538-1552.
  33. Greist JH, Jefferson JW. Anxiety disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1493-1501.
  34. Silberstein SD. Headache - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1715-1725.
  35. Jacewitcz M. Approach to the neurologic patient - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1586-1605.
  36. Eidelberg D, Pourfar M. Movement and cerebellar disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1759-1778.
  37. Rubin M. Peripheral nervous system and motor unit disorders - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1784-1803.
  38. Tunkle AR. Biology of infectious diseases - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 1148-1165.
  39. Crandall JP. Diabetes mellitus and disorders of carbohydrate metabolism - The Merck manual of diagnosis and therapy, 19th edition. Robert S Porter (Ed). Whitehouse station, NJ. Merck Sharp & Dohme Corp., 2011. 866-888.

Additional Resources

  • No Additional Resources Available